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Abstract 
 
Zika virus (ZIKV) infection can result in serious consequences, including severe 
congenital manifestations, persistent infection in the testes and neurologic sequelae. 
After a pandemic emergence, the virus has spread to much of the new world and has 
been introduced to many countries outside of endemic areas as infected travelers return 
to their home countries. Rodent models have been important in gaining a better 
understanding of the wide range of disease etiologies associated with ZIKV infection 
and for the initial phase of developing countermeasures to prevent or treat viral 
infections. We discuss herein the advantages and disadvantages of small animal 
models that have been developed to replicate various aspects of disease associated 
with ZIKV infection. 
 
 
  
Acute viral disease 
 
Table 1. Comparison of the advantages and disadvantages of small animal species 
used to model Zika virus infection and disease. 
      
 Wild-type mice 
Ab-induced 
immune deficient IFN pathway KO STAT2-/- hamsters Guinea pigs 
A
d
v
a
n
ta
g
e
s
 -Readily available 
-Inexpensive 
-Normal immunity 
-Well characterized 
-Diverse immune 
profiles 
-Can use WT mice 
-Induced immune 
deficiency as 
needed 
-Support virus 
replication 
-Age dependent 
disease 
-Virus replication 
-Diverse disease 
manifestations 
-Lethality 
-Intermediate 
sensitivity 
-Persistent infection 
of testes 
-Lower mortality 
rate 
-Similar placentation to 
human 
-Naturally susceptible 
to infection 
-Readily available 
-Normal immunity 
D
is
a
d
v
a
n
ta
g
e
s
 -Naturally resilient 
-Low virus 
replication 
-Requires high 
virus inoculum 
-Difficult infection 
routes 
-Ab expense/ 
availability 
-Reversion to WT 
and clearance of 
virus 
-Little overt 
disease 
-Limited availability 
-May require in-
house colony 
-Sensitive to other 
pathogens 
-Abnormally severe 
disease 
-Lack of reagents 
-Not commercially 
available 
-Variable disease 
manifestation 
-Underlying 
polyoma virus 
-Lack of reagents 
-Large size 
-Not well characterized 
-Expensive to house 
-Somewhat difficult to 
work with. 
 
 
Table 2. Mouse models of acute ZIKV infection and disease. 
Mouse 
strain 
Age 
(wk) 
Virus, dose, 
route 
Pathological findings  
Neurological Other  Ref. 
Porton 0, 4 MR766, 
titration, i.c. 
No disease reported after 
intracerebral inoculation 
LD50 of 107.2 pfu in 1-2 d.o. 
and 106.4 pfu in adult mice 
[1] 
IFNAR-/-or 
AG129  
5, 
11 
Cambodian, 
105 pfu, i.p. 
Brain virus 3, tremors 6 dpi Viremia 2 dpi, virus in 
spleen and testis  
[2] 
AG129 3-4 
or 8 
H/PF/2013, 
100-5 pfu, s.c., 
105.3 pfu, i.p. 
Increased virus in brain, N 
 
Viremia 2 dpi, myofiber 
necrosis, inflammatory cell 
infiltration, nuclear rowing  
[3] 
AG129 8 MR766, 101-5 
pfu, i.p. 
P, C, N, viral Ag in brain 
and spinal cord, acute 
encephalitis 
IFN- and IL-18 increased 
in serum, viral RNA in 
brain, spleen, liver, kidney 
[4] 
IFNAR-/- 5-6 MP1751, 106 
pfu, s.c. 
PC, PMN cells in grey/ 
white matter near blood 
vessels, N in hippocampus.   
Viral RNA in Br and Sp, 3 
dpi, apoptosis in spleen, 
hematopoiesis in liver 
[5] 
AG129 8-10 P 6-740, 103.0 
pfu, s.c 
P, C, Hyper-excitability, 
seizure, tremor. ZIKV Ag in 
neurons, astrocytes. 
Encephalitis and myelitis.  
Viremia peak 5 dpi, virus in 
testis peaks 7 dpi, including 
infected Leydig cells, viral 
RNA shedding in urine 
[6] 
IFNAR-/- 
or Irf3-/-
Irf5-/-Ifr7-/- 
5-6 H/PF/2013 or 
MR766, 102 
ffu, s.c. (f.p.) 
ZIKV RNA in brain and 
spinal cord, higher paralysis 
after i.v. 
Viremia 2-6 dpi, 106 ffu 
virus in testes of IFNAR-/-  
[7] 
C57BL/6 
+ Ifnar Ab 
5 DAKAR, 106.4 
pfu, s.c. or i.p. 
Paralysis 8 dpi after i.p. 
challenge, viral RNA by 
ISH, ND in cerebellum and 
hippocampus 
Viral RNA in brain, kidney, 
skeletal muscle & spleen 3 
dpi, GFAP increase in 
cerebrum, brain titer 15 dpi 
[8] 
C57BL/6, 
IFNAR-/- 
0-1 PRVABC-59, 
103.3-4.3 pfu, 
s.c. 
Wide array of neurologic 
symptoms, virus in neurons 
Inflammatory gene 
increase, T cell driven 
immunity, viral load in brain 
and spleen 
[9] 
STAT2-/-, 
IFNAR-/- 
5-6 MR-766, 103 
pfu, s.c. 
Viral RNA in brain, hind 
limb paralysis, cytokine 
elevations in the brain 
Viral RNA in various 
tissues, upregulated IFN  
[10] 
BALB/c + 
Dexameth 
6-8 PRVABC-59, 
106.5 pfu, i.p. 
Neurons in hippocampus 
stain positive for ZIKV NS1 
Orchitis [11] 
Swiss 0 SPH 2015, i.c. 
or s.c., NP 
Neurological disease and 
death of neurons, gliosis 
Atonic urinary bladder [12] 
STAT2-/- 5-8 PRVABC-59, 
103.7 pfu, i.d. 
Elevated ZIKV replication in 
spinal cord 
Enhanced disease after 
convalescent sera Tx 
[13] 
Abbreviations: pfu - plaque forming unit; i.p. – intra peritoneal; s.c.- sub-cutaneous; i.d. – intradermal; 
TKO – triple knock-out; ffu- focus forming unit; P – paralysis; C – conjunctivitis; N – Neurodegeneration; 
PC – Perivascular cuffing; PMN – polymorphonuclear cells; NP- not provided. 
 
There are many advantages to modeling viral disease in mice and other small 
animal species. Various advantages and disadvantages of rodent species that have 
been used to replicate disease manifestations of Zika virus (ZIKV) disease are included 
in Table 1. This paper will summarize the major findings of work performed in various 
small animal models to characterize disease outcomes after challenge with ZIKV.  
 
Initial studies investigating ZIKV shortly after its discovery in the mid 1900s included 
challenge of various mouse strains, as well as a human challenge model [14-17]. These 
early studies demonstrated that mice were somewhat refractory to ZIKV infection [1], so 
work during the 20th century was limited to around 40 published reports. Emergence of 
ZIKV in the early 21st century resulted in an increased effort to learn more about this 
virus, with around 2,300 papers being published. One of the main goals was to develop 
small animal models for use in delineating the infection cycle, identifying consequences 
of virus infection and discovering antiviral countermeasures. A brief summary of the 
work to develop mouse models of acute ZIKV infection are included in Table 2.  
 
More recent experiments were performed using immune compromised mouse 
strains, which were permissive for virus infection and displayed various neurologic signs 
of disease, including some that replicated severe disease manifestations in humans. 
The AG129 mouse strain, which lacks receptors for IFN-/ and IFN- were susceptible 
to infection after inoculation with various strains of ZIKV injected by various routes [2-4, 
6]. Virus replicates in a wide-range of tissues and viremia can be detected during the 
course of infection, with timing depending on the strain and route of virus. Relevant 
disease signs include eye lacrimation and neurologic involvement. The severity of 
disease observed in this mouse strain underscores the importance of the interferon 
response in controlling ZIKV infection.  
 
Other interferon pathway knockout mice also show varying degrees of disease 
severity after infection with ZIKV and provide a suitable model for virus replication in 
tissues. Infection of IFNAR-/- mice, lacking IFN-/ receptors, with ZIKV results in age-
dependent severity, with mortality occurring in mice that are round 3 weeks or younger 
[2]. The presence of IFN- receptors provides intermediate protection in 5-week old 
mice and complete survival in mice that are 11 weeks. Another knockout mouse strain, 
IFNGR-/- mice, lack IFN- receptors and are susceptible to ZIKV infection. These mice 
and were used to compare the pathogenicity of various ZIKV infectious clones [18]. 
Mosquito transmission of ZIKV to IFNAR-/- mice has helped identify the vector 
competency for several virus strains [19]. STAT2-/- knockout mice and mice lacking 
interferon response factors (Irf) 3, 5 and 7 were also sensitive to intravenous (i.v.) 
infection with ZIKV [7, 10].  
 
Histologic analysis identified ZIKV-positive neurons found throughout the central 
nervous system, including neurodegenerative multifocal neutrophilic encephalitis and 
myelitis. The observation of ZIKV in motor neurons in the ventral horn of the spinal cord 
was similar to disease observed after infection with West Nile virus [20]. Astrocytes 
were also heavily infected in various regions of the brain and spinal cord after ZIKV 
infection, which was similar to pathology observed after challenge of mice with 
Venezuelan equine encephalitis virus, an alphavirus [21]. Interestingly, infected AG129 
mice displayed rear limb myofiber degeneration and necrosis with inflammatory cell 
infiltration in the absence of hind-limb paralysis, suggesting that this virus infects muscle 
cells [3]. Direct intraocular inoculation with ZIKV results in infection of the cells lining the 
blood-retinal barrier and causes chorioretinal atrophy [22]. 
 
Since wild-type mice generally display only a very transient viral infection after ZIKV 
challenge, various methods are used to increase the susceptibility of wild-type, 
immunocompetent strains. Mice can be treated with function-blocking antibodies 
(MAR1-5A3) targeting the IFN-/ receptors to increase the susceptibility of the mice 
just prior to challenge with virus [8]. Viral RNA was detected in the cerebrum and 
hippocampus in mice treated with function-blocking antibody. Dexamethasone 
immunosuppression renders BALB/c mice susceptible to ZIKV infection, resulting in 
detectable virus titer in various tissues and resulting in lethality [11]. Infection of 
neonatal mice shortly after birth also results in morbidity and mortality with more severe 
disease and death observed in the younger mouse pups [12]. Infected neonates 
developed neurologic complications, including tremors, seizure, hyperactivity and limb 
collapse with detectable virus in the brain as late as 15 dpi. 
 
Preexisting flavivirus antibodies (Ab) are implicated in worsened disease during 
infection, a concept known as antibody enhancement of disease. This phenomenon is 
well-known for dengue virus (DENV), where Ab to one strain binds at low levels to an 
incoming heterotypic strain, resulting in an increased uptake of virus by Fc-receptor-
bearing cells of the immune system. Infection in this manner effectively increases the 
host cells available for viral replication and thereby increases the antigen load, host 
response and immunopathology of the infection [23]. This has been demonstrated in 
mouse models of DENV infection [24, 25]. Because of the overlap in sequence between 
DENV and ZIKV, it was also anticipated that antibody enhancement of disease might 
also play a role in ZIKV pathogenesis. although there is no clinical evidence to support 
this idea. Enhanced disease in ZIKV infected mice after treatment with immune serum 
containing Ab to DENV or West Nile virus (WNV) has been demonstrated [13]. 
Enhancement of disease should be carefully considered in the design and 
implementation of vaccines. 
  
Aside from mouse models, other species have been used to model ZIKV, including 
chickens and guinea pigs. Infection of chicken embryos with ZIKV results in virus 
infection of the developing nervous system, causing fetal demise at higher virus 
challenge doses and a microcephaly-like phenotype at lower doses, replicating some 
aspects of congenital infection [26]. Immunocompetent guinea pigs infected with ZIKV 
developed a transient viremia, increase in cytokines and chemokines, infection of 
various tissues and development of neutralizing Abs [27]. These additional models of 
ZIKV infection and disease may provide useful systems for the evaluation of 
countermeasures or in disease characterization.  
 
Congenital infection 
 
Table 3. Rodent models of congenital infection with ZIKV.  
Strain, 
Rodent 
Origin, Virus 
strain 
Infection 
route/dose 
Day of 
gestation 
Major findings Ref. 
IFNAR1-/- 
X 
C57BL/6 
mouse 
French 
Polynesia, 
H/PF/2013 
s.c., f.p./103 ffu E6.5, 7.5 Fetal and placental infection, 
IUGR, fetal demise, placental 
and fetal brain apoptosis 
[28] 
C57BL/6 
mouse 
French 
Polynesia, 
H/PF/2013 
(MAR1-5A3 Ab 
E5.5) s.c., 
f.p./103 ffu 
E6.5, 7.5 Placental and fetal infection, 
IUGR 
[28] 
SJL 
mouse 
Brazil Paraiba 
2015 
i.v./103/1010.6, 
1012 pfu/ml 
E10-13 IUGR, upregulation of 
apoptosis genes, cortical 
malformations 
[29] 
ICR 
mouse 
SZ01 l.v. inj. of 
fetus/105.8 pfu/ml 
(1 µl) 
E13.5 Brain replication in VZ and 
SVZ, cortical thinning, infection 
of NPCs or IPCs 
[30] 
C57BL/6 
mouse 
SZ01 i.u. Fetal Brain 
Inj/105.5 pfu 
E13.5 ZIKV infection of placenta and 
fetal brain, reduction of cortex 
founder cells 
[31] 
C57BL/6, 
IRF3/7-/-, 
IFNAR-/- 
mouse 
Cambodian 
FSS13025 
ivag/104.4-105.7 
pfu 
E4.5-8.5 IUGR, fetal demise, ZIKV 
infection of fetal brain (RNA 
and EM) 
[32] 
CD-1 
mouse 
2010 Cambodia 
2015 Brazil 
2015 Puerto 
Rico 
1968 Nigerian 
i.u., i.p./106 
TCID50 
E10, 14 High aborted fetus rate (30-
45%), virus in fetus/dam and 
IFN 48 hpi w/infection at E10 
(not at E14). Neuroinflam. and 
cortical thinning in neonatal 
brain 
[33] 
STAT2-/- 
hamster 
Malaysia,  
P 6-740 
s.c./102.7 CCID50 E8.5 Virus in fetal brain, placental 
pathology, live births 
[34] 
FVB/NJ 
C57BL/6 
Bahia, Brazil,  
HS-2015-BA-01 
i.v. (jugular)/ 105 
PFU 
E5.5, 7.5, 
9.5 
Infection of placenta/fetus, 
pathology of fetal brain, fetal 
demise, arthrogryposis 
[35] 
Abbreviations: s.c.- sub-cutaneous; f.p.- footpad; E- embryonic day; IUGR- intrauterine growth restriction; 
ffu- focus forming units; i.v.- intravenous; pfu - plaque forming unit; l.v.- lateral ventricle (fetus); VZ- 
ventricular zone; SVZ- subventricular zone; NPC- neural progenitor cells; IPC- intermediate progenitor 
cells; i.u.- intrauterine; inj.- injection; ivag- intravaginal; EM- electron microscopy; i.p.- intraperitoneal; 
TCID50- 50% tissue culture infectious dose; IFN- interferon (type I); CCID50- 50% cell culture infectious 
dose; 
 
Intrauterine exposure of a developing fetus to ZIKV infection can result in debilitating 
manifestations in the fetus, the most severe and obvious of which is microcephaly. An 
increase in the incidence of microcephaly during the recent ZIKV outbreak in Brazil 
eventually led to the discovery of the causative role of the virus in developmental 
abnormalities of fetuses after exposure in utero. Aside from microcephaly, other disease 
manifestations have been reported, including smaller birthweight, brain abnormalities 
despite normal head size, hearing loss, optic nerve hypoplasia, joint and bone 
deformities (arthrogryposis), and many other less apparent effects of ZIKV congenital 
exposure [36]. A significantly (P<0.0001) higher mortality rate (~5.1%) of fetuses was 
associated with ZIKV infection cases as compared with other etiologies (~1.4%) in 
pregnant women in Brazil [37]. This article will focus on various consequences of 
intrauterine exposure to ZIKV that have been replicated in small animal models as well 
as those aspects of congenital infection that are dissimilar between rodents and 
humans. 
 
In attempting to recapitulate disease associated with intrauterine infection in small 
animal models, various laboratories have independently developed mouse models of 
congenital infection (Table 3). Despite the use of a diverse range of ZIKV strains, as 
well as differences in dose, route and timing of infection during gestation, some 
consistent consequences of infection have been delineated in rodents. Virus was 
generally detected in the placenta [28, 31, 34, 35], while fetal infection was dependent 
on timing of maternal challenge and typically correlated with virus titer in the placenta. A 
gestational time-dependent transmission was also observed, with lower fetal infection 
rates at later stages of gestation. Another commonly observed consequence was 
intrauterine growth restriction (IUGR) and spontaneous abortion of developing fetuses 
[28, 29, 32]. These findings are similar to outcomes in natural congenital infection and 
can be used to further characterize congenital infection as well as to identify 
countermeasures to inhibit or prevent fetal infection. The period between embryonic day 
(E)3 and E14, when pregnant mice have been challenged with ZIKV across several 
studies, corresponds with days 4-48 of human gestation during the first trimester. 
 
The interaction between virus in maternal blood and fetal tissues occurs in the 
placenta. Although the placental structure of mice is quite distinct from that of humans, 
there are various similarities that are found between the two that make the mouse a 
reasonable model for various aspects of human placentation, including notably the 
lining of fetal structures with syncytiotrophoblast cells that contact maternal blood [38]. 
Trophoblast cells of the mouse conceptus will differentiate, forming a branched villious 
structure, which invades the placental wall decidua beginning around E8.5. The 
placenta of mice is considered functional at approximately 10 days post-coitus (dpc) 
[39-41]. 
 
The timing of virus challenge during pregnancy is important in the context of 
congenital infection of the fetus in rodent models. Congenital infection of mice with other 
flaviviruses was demonstrated when virus challenge occurred between E5 and E12, but 
detection of virus or viral antigen in the fetus was less likely as development proceeded 
past E12 [42, 43]. Similar observations have been reported with ZIKV infection in mouse 
models [33, 35]. Although peripheral challenge of pregnant dams with ZIKV after E12 
results in virus infection of the placenta, infection at this time does not typically result in 
fetal infection in rodents. The timing of reduced congenital virus infection in rodents 
appears to be associated with placental development. This is somewhat dissimilar to 
congenital infection in humans, where ZIKV infection during the second and third 
trimester can result in transmission to the fetus. This observation could indicate partial 
control of the dissemination of virus to the fetus at the placental barrier, or could 
suggest other mechanisms involved with transplacental infection. 
 
A functional placenta is present in mice around E10. Challenge of mice between E4 
and E14 results in productive placental infection in mice. The detection of virus in the 
placenta after challenge from E4 to E14 sugests a high degree of susceptibility of this 
organ [33]. After the development of a functional placenta in mice, transplacental 
transmission of ZIKV and other flaviviruses to the fetus is reduced, unless the fetuses 
are challenged directly [30, 31, 33]. The lack of infection at later times in mice may 
suggest the placental barrier is preventing transplacental movement of ZIKV in the 
mouse. However, this is dissimilar to congenital infection of human fetuses, where brain 
lesions have been observed in newborn babies after ZIKV infection during the second 
and third trimester of pregnancy [44]. However, these second and third trimester 
infections of human placentas appear to be limited primarily to Hofbauer cells (HBCs) 
and the inflammatory villitis that is seen during first trimester placental infections is 
reportedly absent at later infection times [45]. Indeed, HBCs isolated from human 
placentas have been the focus of several studies, which demonstrate susceptibility of 
these cells to ZIKV [45-47]. In contrast, infection of the placenta during the first trimester 
of human pregnancy results in the infection in a wider array of placental cells. 
Mesenchymal cells and cytotrophoblasts support ZIKV replication along with HBCs. 
This gestationally-dependent infection of placental cells was further supported by a 
study that demonstrated expression of genes for various entry factors utilized by ZIKV in 
early-stage type trophoblast cells [48]. These cells were highly susceptible to infection in 
cell culture, while cells isolated from term placentas did not express these genes and 
were relatively resilient to ZIKV infection. While mice and humans may differ in some 
aspects of congenital infection, challenge of pregnant mice during early (prior to E10) 
gestation models many aspects of natural infection. 
 
Most of the studies have terminated at some point during gestation and few live 
births have been recorded. The consequences of intrauterine exposure to ZIKV on the 
development of neonates will be an important step in future research to further identify 
consequences of congenital infection. Depending on the strain of virus used, the 
immune state of the dam, and the timing of infection, the aborted fetus rate can be 
relatively high [33], which would result in fewer births. Disease manifestations in 
females just after birth may cause the dams to neglect or cannibalize pups [34], further 
complicating studies designed to characterize the effect of intrauterine exposure to ZIKV 
on the development of neonates. Future studies should include live births to determine 
the suitability of mice to model the effects of intrauterine infection on developing 
neonates. 
 
Sexual transmission  
Table 4.  
Model Virus origin, 
strain 
Infection 
route/dose 
Major findings Reference 
C57BL/6 
(MAR1-5A3) 
Rag1-/- 
Axl-/- mice 
Dakar 41519 
(ma) 
H/PF/2013 
s.c. 
(f.p.)/106.0 pfu 
103.0 pfu 
 
Persistence of ZIKV in T/E (21 dpi), 
reduced testis size, low 
testosterone, infected 
spermatogonia, seminiferous tubule 
degradation 
[49] 
IFNAR-/- mice MEX2-81 s.c. (f.p.)/105 
pfu 
Presence of viral RNA in T/E 21 
dpi, T atrophy, reduced 
testosterone 
[50] 
IFNAR-/- mice ZIKA-SMGC-
1 
i.p./103.0 pfu 
i.t./102.6 pfu 
Atrophy of the repro tract, virus in 
T/E, not seminal vesicle or prostate 
[51] 
AG129 mice Puerto Rico, 
PRVABC59 
i.p./103 pfu ZIKV RNA/virus observed in 
semen, demonstration of sexual 
transmission of virus and fetal 
infection, virus/inflammation in T/E 
[52] 
STAT2-/- 
hamster 
P 6-740 s.c./102.7 
CCID50 
Infection of Sertoli cells and 
spermatogonia 
[34] 
BALB/c mice 
(dexameth.) 
Puerto Rico, 
PRVABC59 
i.p./106.5 pfu Pathology of seminiferous tubules, 
lymphocytic infiltration (12-14 dpi), 
reduced viral load in T/E and 
prostate after IFN treatment 
[53] 
 
 
AG129 and 
LysMCre+IFNAR 
Cambodia, 
FSS13025 
Ivag/ 105 or 
106 ffu 
Estrus cycle-dependent 
susceptibility of females 
[54] 
IFNAR-/- mice Puerto Rico, 
PRVABC59 
Rectal/106.5 
pfu 
Nonlethal, virus in rectum, testis, 
brain and spleen d21, inflammation 
and splenomegaly 
Martinez 
et al., 
2017 
Abbreviations: s.c.- sub-cutaneous; f.p.- footpad; pfu- plaque forming units; T- testicle; E- epididymis; i.p.- 
intraperitoneal; i.t.- intratesticular; s.c.- sub-cutaneous; dpi- days post-virus injection; Ivag- intravaginal; 
ffu- focus forming units; 
 
A somewhat unanticipated consequence of ZIKV infection is sexual transmission. 
Evidence of non-mosquito transmission was available as early as 2008, where a 
returning scientist that was infected with ZIKV in Senegal transmitted the virus to his 
wife, which was suspected to be through sexual contact [55]. Closely related 
flaviviruses, such as dengue virus, are not known to be transmitted through sexual 
contact. It has been well documented that men that were exposed to ZIKV in endemic 
areas could further spread the virus to their sexual partners, which may or may not 
include the manifestation of disease. Various clinical studies have provided evidence of 
sexual transmission of ZIKV from male-to-female, female-to-male and male-to-male [56-
60]. Transmission has been reported to occur several weeks after returning from areas 
of endemicity and virus (typically viral RNA) could be recovered from the semen of 
infected males up to 6 months after disease onset [61]. While little is known about the 
localization of virus in the reproductive tract of infected men, mouse models have 
provided insight into which cell types are infected and potential mechanisms of sexual 
transmission (Table 4).  
 
Many published reports have demonstrated ZIKV infection of the male reproductive 
tract of rodents, primarily indicating detection of infectious virus or viral RNA in the 
testes of infected males [2, 4, 6, 7]. The testes support very high levels of virus, 
particularly in immunocompromised mice. Virus has been localized in various cells of 
the testis, including Leydig cells, spermatogenic precursors, and in epithelial cells of the 
epididymis [34, 52]. Interstitial inflammation and inflammatory cell infiltrates were 
observed. Necrotic cells that stained positively for viral antigen were observed in the 
lumen of the epididymides [49], representing a potential source of virus for transmission. 
Other severe disease manifestions, such as orchitis and testicular atrophy, have been 
observed in mouse models [50]. 
 
The implications of testis infection observed in mice may not be directly translatable 
to human infection. For example, orchitis, or inflammation of the testicle, is a very 
painful condition in people and is generally the consequence of bacterial infection, 
including sexually transmitted infections. This is commonly observed in immune 
suppressed mice infected with ZIKV [11, 51]. If a common consequence of ZIKV in 
infected men was orchitis, the pain would be intense and they would surely seek 
medical attention. Orchitis is likely not a commonly occurring consequence of ZIKV 
infection of the male reproductive tract. 
 
Intravaginal infection of female mice with ZIKV can cause a systemic infection and 
may also be transmitted to offspring [52, 54]. The estrous cycle may influence the 
susceptibility of females, as AG129 mice that were inoculated intravaginally with ZIKV 
during a hormonally-induced estrus-like phase did not succumb to viral infection and 
had a relative lack of virus replication in various tissues, while those that were in an 
induced diestrus-like phase displayed virus replication and mortality [54]. Transmission 
from infected males to naïve females has been demonstrated in AG129 mice, including 
transmission from vasectomized mice, despite a lower virus load as compared with 
intact males [52]. Males also had detectable virus in the semen several weeks after 
virus challenge, modeling persistent virus present in men infected naturally with ZIKV. 
Rectal inoculation of male mice results in systemic spread of virus to various tissues, 
including the testes and supports observations of male-to-male transmission (Martinez, 
2017 preprint). 
 
Use of models in the development of countermeasures 
Table 5. Various anti-ZIKV countermeasures have been tested in small animal models. 
 Strain, age Virus strain Treatment protocol Outcome Ref 
A
n
ti
v
ir
a
ls
 AG129,  
8-14 wks 
MR766  7 DMA, p.o., 50 
mg/kg/d, qd X 10 
beginning -1 hour 
Reduced viremia by 0.5-1.3 log10, 
delayed MDD 15-23 dpi 
[4] 
AG129,  
8-10 wks 
P 6-740 
 
BCX4430, 300 
mg/kg/d, i.m., bid X 7 
beginning 0-7 dpi  
Reduced viremia on 5 dpi by ~2 log10, 
delayed or prevented death, reduced 
disease, survive re-challenge 
[6] 
IFNAR-/-, 4 
wk 
GZ01/2016  NITD008, 50mg/kg, 
p.o at 4,24,48,72 and 
96 hpi 
Reduced viremia 2.6-fold on 2dpi, 
50% survival, reduced disease signs  
[62] 
C57BL/6 + 
Ifnar1 mAb 
DAKAR 
41519 
Sofosbuvir, 33 
mg/kg/d, oral X 7, beg. 
24 hpi 
Improved survival, extended MDD [63] 
BALB/c, 6-
8 wks + 
DEX  
PRVABC-59 Peg. IFN-2b, 103.3 IU, 
s.c., q 96 h, 1-9 dpi 
Reduced viral loads in various 
tissues, 100% survival, no prominent 
inflammation in any of the tissues 
tested 
[11] 
IFN-1b, 105.2 IU/dose, 
i.p., q 48 h, 1-9 dpi 
A
n
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Prenant 
ICR mice 
E13.5 
SZ01 Convalescent sera, 
100 µL, i.p. E14.5 (1 
dpi) and E15.5 (2 dpi).  
Neutralizing Ab titer of 161, reduced 
caspase-3 in cortex, rescued cortical 
plate thinning 
[64] 
IFNAR-/- H/PF/2013 Human mAb from 
DENV patients, 10µg, 
i.p., -1 and 9 dpi  
mAbs EDE1-C10 neutralized ZIKV, 
100% survival 
[65] 
C57BL/6 + 
Ifnar1 mAb 
ZIKV- Dakar  mAb ZIKV-117, from 
human antisera, i.p., 
6.7 mg/kg 1 dpi or 
16.7 mg/kg, 5 dpi 
100% survival (1 dpi) or 70-75% (5 
dpi). Reduced transmission, 
pathology and mortality  
[66] 
Ifnar1-/- 
female X 
WT male 
ZIKV- Dakar 
(E6.5) 
mAb ZIKV-117, dams 
treated with 6.7 mg/kg, 
1 dpi or 16.7 mg/kg, 5 
dpi 
4-5 log10 reduced virus in fetal and 
maternal tissues, protection in 
pregnancy model due to neutralization 
Pregnant 
C57BL/6 
mice 
ZIKV- Dakar 
(E5.5)  
mAb ZIKV-117, dams 
treated with 16.7 
mg/kg 1 dpi 
Reduced virus in dams, placenta and 
fetus, improved fetal, placental 
disease, prevents vertical 
transmission 
V
a
c
c
in
e
 
AG129, 4-6 
wks 
FSS13025 
or MR 766 
Inactivated MR 766 
virus, vaccine 10 µg / 
dose, 0 and 21 days, 
i.m. 
100% survival in MR 766 & 
FSS13025 infection, 100% survival, 
absence of detectable viremia in 
serum up to 6 dpi. 
[67] 
BALB/c, 
C57BL/6 or 
SJL, 4 wk  
ZIKV2015, 
PRVABC-59 
 
DNA-prM-Env or DNA-
Env vaccines, 50 µg, 
i.m, -28 dpi 
Reduced viremia, correlation of 
efficacy w/ neutAb, Ab transfer 
improves 
[68] 
IFNAR-/-  FSS13025 10-del ZIKV, route, -4 
wks 
High neutAb, robust T cell response, 
100% survival, undetectable viremia. 
[69] 
CD-1, 1 
day old 
FSS13025 10-del ZIKV, as above 100% survival  
AG129, 6 
wks  
P6-740 prM-E mRNA, -6 wks  High neutAb, 100% survival [70] 
C57BL/6 + 
Ifnar1 mAb, 
8 or 18 wk 
Dakar 
41519 
modified prM-E 
mRNA, -6 wks 
High neutAb, 100% survival 
C57BL/6, 
BALB/c 
MR-766 VSV-ZprME, VSV-
ZENV, i.v. or i.m., -3 
wks 
Offspring born to vaccinated females 
were protected from challenge on 
PND7 
[71] 
Abbreviations: wks – weeks; p.o- per os; qd- once a day; dpi- days post-virus injection; i.m. – 
intramuscular; bid- twice a day; i.p – intraperitoneal; hpi- hours post-virus injection; pfu - plaque forming 
unit; MDD - mean day-to-death; neutAb- neutralizing antibody; s.c.- subcutaneous; i.d. – intradermal; i.c – 
intracerebral; RDRP – RNA dependent RNA polymerase; i.v – intravenous; ffu – focus forming unit; conv-
convlescent serum; PND- post-natal day. 
 
As there are currently no FDA-approved drugs to treat acute flaviviral diseases, it is 
unknown how direct-acting antiviral compounds would impact infection and disease 
outcome in people infected with ZIKV. There is potential for antiviral treatment to reduce 
disease burden and further spread of the virus if therapy is initiated soon after the onset 
of clinical disease or if prophylactic treatment, in the context of a wide-spread viral 
outbreak, is used. In regards to the treatment of Zika, antiviral agents could have use in 
preventing fetal transmission, clearing sequelae from the testes or reducing viral load 
during acute infection to reduce or inhibit further transmission. 
 
Various nucleoside analogs, including 7-deaza-2’-C-Methyladenosine (7DMA), 
BCX4430, sofosbuvir and NITD008 have been shown to be active against ZIKV in cell 
culture and in mouse models [4, 6, 62, 63]. These viral RNA-dependent RNA 
polymerase (RdRp) inhibitors delay or prevent mortality, reduce virus titer in relevant 
tissues, and improve disease in infected mice. Although these broad-spectrum antivirals 
did not completely eliminate disease, efficacy in knockout mouse models was 
nevertheless impressive due to the acute sensitivity of these mice to ZIKV and would 
likely fare better against natural infection in an immunocompetent host. Sofosbuvir is an 
FDA-approved drug used to treat chronic hepatitis C virus (HCV) [72]. If this compound 
has clinical efficacy against ZIKV, the approval process would be truncated as the 
compound is well-characterized for human administration. BCX4430 has been shown to 
be effective against a wide range of viruses of human concern [73-75]and clinical trials 
have been initiated. NITD008 was initially identified as a potential antiviral to treat 
DENV, but had toxicity after long-term treatment [76]. Short-term treatment, applicable 
to treatment of acute arboviral diseases, did not result in appreciable toxicity and further 
clinical investigation may be warranted. Broad-spectrum activity of NITD008 has also 
been observed in various animal models [76, 77]. 
 
Indirect acting antiviral agents have also been identified to have activity against ZIKV 
in mouse models. The compound 25 hydroxy cholesterol (25HC) is an enzymatic 
product of cholesterol-25-hydroxylase. Treatment with 25HC reduced ZIKV viremia by 
blocking viral entry in mice and macaques, including reduction of microcephaly in a 
congenital model [75]. Azithromycin, a macrolide antibiotic that is FDA-approved for use 
including during pregnancy, prevented ZIKV production and viral mediated cell death in 
primary human brain tissue by reducing viral proliferation and cytopathic effects in glial 
cells and astrocytes [78]. However, activity has not yet been demonstrated in a small 
animal model.  
 
Antibody (Ab) therapy has been used to control virus infection and disease during 
outbreaks [79]. Antibodies targeting the envelope (E) protein, and in particular domain 
III, have been shown to include potent neutralizers that would be suitable for use in 
therapy [80, 81]. Efficient neutralizing Abs have been isolated from the serum of people 
that have been infected with ZIKV, revealing the importance of antibodies targeting the 
envelope protein (E) in the context of clearance of ZIKV infection [66]. Some of these 
antibodies have shown activity in mouse models, and are effective in preventing or 
reducing disease after ZIKV infection, including prevention of congenital infection after 
treatment of pregnant dams [64, 66]. This is consistent with previous studies with the 
related WNV, where prevention of congenital infection was observed in rodent models 
treated with pooled human immune serum [82].  
 
Care must be taken in regard to use of Ab therapy in the context of ZIKV, as 
treatment with convalescent plasma from donors possessing Abs specific for 
flaviviruses, including DEN and WNV, may enhance disease [13]. Antibodies containing 
mutations in the Fc receptor region maintain the specificity and neutralizing capabilities 
of the Ab, but remove the possibility for negative enhancement interactions of Ab with 
immune cells. Antibodies with inactivated Fc receptor have been shown to be effective 
in small animal models [66].  
 
Vaccines are very important in controlling acute arboviral diseases and have 
demonstrated efficacy in substantially reducing the disease burden of yellow fever virus 
(YFV), the archetypical flavivirus [83]. Various types of vaccines have been developed 
to protect against ZIKV (Table 5) and additional studies are being published at a rapid 
pace. Inactivated or attenuated viruses may also elicit long-term immunity as is the case 
with the attenuated 17D YFV vaccine. Inactivated and modified live-attenuated (10 
nucleotide deletion in in the 3’-UTR) viruses have shown promise in preventing ZIKV in 
mouse models [67, 69]. Development of vaccines that target the E protein have been 
prominent and show promise in various animal models [68, 70]. As with Ab therapy, an 
important question in regard to vaccine development is whether the Abs elicited by 
vaccination might serve to enhance infection with ZIKV. Some reports of enhancement 
in small animal models have been reported [13].  
  
Conclusions 
Small animal models are important in delineating the consequences of ZIKV. The 
use of various rodent species and strains, including genetic knockouts, has provided 
useful information to help us better understand disease as a result of infection with this 
virus. Continued efforts will provide information to aid in the development of 
countermeasures to reduce the disease burden of this emerging virus. 
 
 
References: 
1. Way JH, Bowen ET, Platt GS. Comparative studies of some African arboviruses in cell culture 
and in mice. J Gen Virol 1976; 30:123-30. 
2. Rossi SL, Tesh RB, Azar SR, et al. Characterization of a Novel Murine Model to Study Zika 
Virus. Am J Trop Med Hyg 2016. 
3. Aliota MT, Caine EA, Walker EC, Larkin KE, Camacho E, Osorio JE. Characterization of Lethal 
Zika Virus Infection in AG129 Mice. PLoS Negl Trop Dis 2016; 10:e0004682. 
4. Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJ, Neyts J. The Viral Polymerase 
Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication 
and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Negl Trop Dis 2016; 
10:e0004695. 
5. Dowall SD, Graham VA, Rayner E, et al. A Susceptible Mouse Model for Zika Virus Infection. 
PLoS Negl Trop Dis 2016; 10:e0004658. 
6. Julander JG, Siddharthan V, Evans J, et al. Efficacy of the broad-spectrum antiviral compound 
BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res 2016; 137:14-22. 
7. Lazear HM, Govero J, Smith AM, et al. A Mouse Model of Zika Virus Pathogenesis. Cell Host 
Microbe 2016; 19:720-30. 
8. Smith DR, Hollidge B, Daye S, et al. Neuropathogenesis of Zika Virus in a Highly Susceptible 
Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. PLoS Negl Trop 
Dis 2017; 11:e0005296. 
9. Manangeeswaran M, Ireland DD, Verthelyi D. Zika (PRVABC59) Infection Is Associated with T 
cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice. 
PLoS Pathog 2016; 12:e1006004. 
10. Tripathi S, Balasubramaniam VR, Brown JA, et al. A novel Zika virus mouse model reveals 
strain specific differences in virus pathogenesis and host inflammatory immune responses. PLoS 
Pathog 2017; 13:e1006258. 
11. Chan JF, Zhang AJ, Chan CC, et al. Zika Virus Infection in Dexamethasone-
immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement 
Including Orchitis Effectively Treated by Recombinant Type I Interferons. EBioMedicine 2016; 
14:112-22. 
12. Fernandes NC, Nogueira JS, Ressio RA, et al. Experimental Zika virus infection induces spinal 
cord injury and encephalitis in newborn Swiss mice. Exp Toxicol Pathol 2017; 69:63-71. 
13. Bardina SV, Bunduc P, Tripathi S, et al. Enhancement of Zika virus pathogenesis by 
preexisting antiflavivirus immunity. Science 2017; 356:175-80. 
14. Bearcroft WG. Zika virus infection experimentally induced in a human volunteer. Trans R Soc 
Trop Med Hyg 1956; 50:442-8. 
15. Dick GW. Zika virus. II. Pathogenicity and physical properties. Trans R Soc Trop Med Hyg 
1952; 46:521-34. 
16. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R 
Soc Trop Med Hyg 1952; 46:509-20. 
17. Reagan RL, Chang SC, Brueckner AL. Electron micrographs of erythrocytes from Swiss albino 
mice infected with Zika virus. Tex Rep Biol Med 1955; 13:934-8. 
18. Widman DG, Young E, Yount BL, et al. A Reverse Genetics Platform That Spans the Zika Virus 
Family Tree. mBio 2017; 8. 
19. Roundy CM, Azar SR, Rossi SL, et al. Variation in Aedes aegypti Mosquito Competence for 
Zika Virus Transmission. Emerg Infect Dis 2017; 23:625-32. 
20. Siddharthan V, Wang H, Motter NE, et al. Persistent West Nile virus associated with a 
neurological sequela in hamsters identified by motor unit number estimation. J Virol 2009; 
83:4251-61. 
21. Julander JG, Skirpstunas R, Siddharthan V, et al. C3H/HeN mouse model for the evaluation 
of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral 
Res 2008; 78:230-41. 
22. Singh PK, Guest JM, Kanwar M, et al. Zika virus infects cells lining the blood-retinal barrier 
and causes chorioretinal atrophy in mouse eyes. JCI Insight 2017; 2:e92340. 
23. Halstead SB. Pathogenesis of Dengue: Dawn of a New Era. F1000Res 2015; 4. 
24. Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in 
mice is prevented by Fc modification. PLoS Pathog 2010; 6:e1000790. 
25. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial 
cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010; 
7:128-39. 
26. Goodfellow FT, Tesla B, Simchick G, et al. Zika Virus Induced Mortality and Microcephaly in 
Chicken Embryos. Stem Cells Dev 2016; 25:1691-7. 
27. Kumar M, Krause KK, Azouz F, Nakano E, Nerurkar VR. A guinea pig model of Zika virus 
infection. Virol J 2017; 14:75. 
28. Miner JJ, Cao B, Govero J, et al. Zika Virus Infection during Pregnancy in Mice Causes 
Placental Damage and Fetal Demise. Cell 2016; 165:1081-91. 
29. Cugola FR, Fernandes IR, Russo FB, et al. The Brazilian Zika virus strain causes birth defects 
in experimental models. Nature 2016; 534:267-71. 
30. Li C, Xu D, Ye Q, et al. Zika Virus Disrupts Neural Progenitor Development and Leads to 
Microcephaly in Mice. Cell Stem Cell 2016. 
31. Wu KY, Zuo GL, Li XF, et al. Vertical transmission of Zika virus targeting the radial glial cells 
affects cortex development of offspring mice. Cell Res 2016; 26:645-54. 
32. Yockey LJ, Varela L, Rakib T, et al. Vaginal Exposure to Zika Virus during Pregnancy Leads to 
Fetal Brain Infection. Cell 2016; 166:1247-56 e4. 
33. Vermillion MS, Lei J, Shabi Y, et al. Intrauterine Zika virus infection of pregnant 
immunocompetent mice models transplacental transmission and adverse perinatal outcomes. 
Nat Commun 2017; 8:14575. 
34. Siddharthan V, Van Wettere AJ, Li R, et al. Zika virus infection of adult and fetal STAT2 
knock-out hamsters. Virology 2017; 507:89-95. 
35. Xavier-Neto J, Carvalho M, Pascoalino BD, et al. Hydrocephalus and arthrogryposis in an 
immunocompetent mouse model of ZIKA teratogeny: A developmental study. PLoS Negl Trop 
Dis 2017; 11:e0005363. 
36. Moore CA, Staples JE, Dobyns WB, et al. Characterizing the Pattern of Anomalies in 
Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatr 2017; 171:288-95. 
37. Franca GV, Schuler-Faccini L, Oliveira WK, et al. Congenital Zika virus syndrome in Brazil: a 
case series of the first 1501 livebirths with complete investigation. Lancet 2016; 388:891-7. 
38. Rossant J, Cross JC. Placental development: lessons from mouse mutants. Nat Rev Genet 
2001; 2:538-48. 
39. Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: key pieces of the development 
puzzle. Science 1994; 266:1508-18. 
40. Enders AC. A Comparative Study of the Fine Structure of the Trophoblast in Several 
Hemochorial Placentas. Am J Anat 1965; 116:29-67. 
41. Georgiades P, Ferguson-Smith AC, Burton GJ. Comparative developmental anatomy of the 
murine and human definitive placentae. Placenta 2002; 23:3-19. 
42. Julander JG, Winger QA, Rickords LF, et al. West Nile virus infection of the placenta. Virology 
2006; 347:175-82. 
43. Mathur A, Arora KL, Chaturvedi UC. Congenital infection of mice with Japanese encephalitis 
virus. Infect Immun 1981; 34:26-9. 
44. Victora CG, Castro MC, Franca GV, Schuler-Faccini L, Barros FC. Zika rash and increased risk 
of congenital brain abnormalities - Authors' reply. Lancet 2017; 389:152. 
45. Schwartz DA. Viral infection, proliferation, and hyperplasia of Hofbauer cells and absence of 
inflammation characterize the placental pathology of fetuses with congenital Zika virus 
infection. Arch Gynecol Obstet 2017. 
46. Rosenberg AZ, Yu W, Hill DA, Reyes CA, Schwartz DA. Placental Pathology of Zika Virus: Viral 
Infection of the Placenta Induces Villous Stromal Macrophage (Hofbauer Cell) Proliferation and 
Hyperplasia. Arch Pathol Lab Med 2017; 141:43-8. 
47. Simoni MK, Jurado KA, Abrahams VM, Fikrig E, Guller S. Zika virus infection of Hofbauer 
cells. Am J Reprod Immunol 2017; 77. 
48. Sheridan MA, Yunusov D, Balaraman V, et al. Vulnerability of primitive human placental 
trophoblast to Zika virus. Proc Natl Acad Sci U S A 2017; 114:E1587-E96. 
49. Govero J, Esakky P, Scheaffer SM, et al. Zika virus infection damages the testes in mice. 
Nature 2016; 540:438-42. 
50. Uraki R, Hwang J, Jurado KA, et al. Zika virus causes testicular atrophy. Sci Adv 2017; 
3:e1602899. 
51. Ma W, Li S, Ma S, et al. Zika Virus Causes Testis Damage and Leads to Male Infertility in 
Mice. Cell 2016; 167:1511-24 e10. 
52. Duggal NK, Ritter JM, Pestorius SE, et al. Frequent Zika Virus Sexual Transmission and 
Prolonged Viral RNA Shedding in an Immunodeficient Mouse Model. Cell Rep 2017; 18:1751-60. 
53. Costa F, Sarno M, Khouri R, et al. Emergence of Congenital Zika Syndrome: Viewpoint From 
the Front Lines. Ann Intern Med 2016. 
54. Tang WW, Young MP, Mamidi A, Regla-Nava JA, Kim K, Shresta S. A Mouse Model of Zika 
Virus Sexual Transmission and Vaginal Viral Replication. Cell Rep 2016; 17:3091-8. 
55. Foy BD, Kobylinski KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika 
virus, Colorado, USA. Emerg Infect Dis 2011; 17:880-2. 
56. D'Ortenzio E, Matheron S, Yazdanpanah Y, et al. Evidence of Sexual Transmission of Zika 
Virus. N Engl J Med 2016; 374:2195-8. 
57. Davidson A, Slavinski S, Komoto K, Rakeman J, Weiss D. Suspected Female-to-Male Sexual 
Transmission of Zika Virus - New York City, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:716-
7. 
58. Deckard DT, Chung WM, Brooks JT, et al. Male-to-Male Sexual Transmission of Zika Virus - 
Texas, January 2016. MMWR Morb Mortal Wkly Rep 2016; 65:372-4. 
59. Hills SL, Russell K, Hennessey M, et al. Transmission of Zika Virus Through Sexual Contact 
with Travelers to Areas of Ongoing Transmission - Continental United States, 2016. MMWR 
Morb Mortal Wkly Rep 2016; 65:215-6. 
60. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual 
transmission of Zika virus. Emerg Infect Dis 2015; 21:359-61. 
61. Moreira J, Peixoto TM, Siqueira AM, Lamas CC. Sexually acquired Zika virus: a systematic 
review. Clin Microbiol Infect 2017. 
62. Deng YQ, Zhang NN, Li CF, et al. Adenosine Analog NITD008 Is a Potent Inhibitor of Zika 
Virus. Open Forum Infect Dis 2016; 3:ofw175. 
63. Bullard-Feibelman KM, Govero J, Zhu Z, et al. The FDA-approved drug sofosbuvir inhibits 
Zika virus infection. Antiviral Res 2017; 137:134-40. 
64. Wang Q, Yang H, Liu X, et al. Molecular determinants of human neutralizing antibodies 
isolated from a patient infected with Zika virus. Sci Transl Med 2016; 8:369ra179. 
65. Swanstrom JA, Plante JA, Plante KS, et al. Dengue Virus Envelope Dimer Epitope Monoclonal 
Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. mBio 2016; 7. 
66. Sapparapu G, Fernandez E, Kose N, et al. Neutralizing human antibodies prevent Zika virus 
replication and fetal disease in mice. Nature 2016; 540:443-7. 
67. Sumathy K, Kulkarni B, Gondu RK, et al. Protective efficacy of Zika vaccine in AG129 mouse 
model. Sci Rep 2017; 7:46375. 
68. Larocca RA, Abbink P, Peron JP, et al. Vaccine protection against Zika virus from Brazil. 
Nature 2016; 536:474-8. 
69. Shan C, Muruato AE, Nunes BTD, et al. A live-attenuated Zika virus vaccine candidate 
induces sterilizing immunity in mouse models. Nat Med 2017. 
70. Richner JM, Himansu S, Dowd KA, et al. Modified mRNA Vaccines Protect against Zika Virus 
Infection. Cell 2017; 168:1114-25 e10. 
71. Betancourt D, de Queiroz NM, Xia T, Ahn J, Barber GN. Cutting Edge: Innate Immune 
Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective 
Immunity. J Immunol 2017; 198:3023-8. 
72. Olsen DB, Eldrup AB, Bartholomew L, et al. A 7-deaza-adenosine analog is a potent and 
selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. 
Antimicrob Agents Chemother 2004; 48:3944-53. 
73. Julander JG, Bantia S, Taubenheim BR, et al. BCX4430, a novel nucleoside analog, effectively 
treats yellow fever in a Hamster model. Antimicrob Agents Chemother 2014; 58:6607-14. 
74. Taylor R, Kotian P, Warren T, et al. BCX4430 - A broad-spectrum antiviral adenosine 
nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public 
Health 2016; 9:220-6. 
75. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-
spectrum nucleoside analogue BCX4430. Nature 2014; 508:402-5. 
76. Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl 
Acad Sci U S A 2009; 106:20435-9. 
77. Nelson J, Roe K, Orillo B, Shi PY, Verma S. Combined treatment of adenosine nucleoside 
inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy 
strategy to ameliorate West Nile virus infection. Antiviral Res 2015; 122:39-45. 
78. Retallack H, Di Lullo E, Arias C, et al. Zika virus cell tropism in the developing human brain 
and inhibition by azithromycin. Proc Natl Acad Sci U S A 2016; 113:14408-13. 
79. Winkler AM, Koepsell SA. The use of convalescent plasma to treat emerging infectious 
diseases: focus on Ebola virus disease. Curr Opin Hematol 2015; 22:521-6. 
80. Diamond MS, Pierson TC, Fremont DH. The structural immunology of antibody protection 
against West Nile virus. Immunol Rev 2008; 225:212-25. 
81. Sukupolvi-Petty S, Austin SK, Purtha WE, et al. Type- and subcomplex-specific neutralizing 
antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent 
epitopes. J Virol 2007; 81:12816-26. 
82. Julander JG, Winger QA, Olsen AL, Day CW, Sidwell RW, Morrey JD. Treatment of West Nile 
virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam 
survival. Antiviral Res 2005; 65:79-85. 
83. Monath TP. Review of the risks and benefits of yellow fever vaccination including some new 
analyses. Expert review of vaccines 2012; 11:427-48. 
 
